Table 4 Medication Trials in Hepatitis B and Hepatitis C Coinfected Patients

Anti-HCV+

HCV RNA+

HBsAg+

HBV DNA-

16

IFNα 3 MU TIW × 6 mo

N/A

N/A

12.5%

N/A

19%

Anti-HCV+

HBsAg+

8

IFNα 3 MU TIW × 6 mo

N/A

N/A

12.5%

N/A

12.5%

Anti-HCV+

HCV RNA+

HBsAg+

HBV DNA+

7

IFNα 6 MU TIW × 6 mo

29%

86%

28.6%

100%

0%

Anti-HCV+

HCV RNA+

HBsAg+

30

IFNα 9 MU TIW × 6 mo or 6 MU TIW × 6 mo

16.7% (31%)*

66.7% (100%)*

3%

N/A

20% (37.5%)*

Anti-HCV+

HBeAg ±

HCV RNA ±

16

IFNα 5 MU TIW × 12 mo

43.8%

N/A

N/A

15.4%

50%

Anti-HCV+

HBV DNA+

HBsAg-

14

IFNα 3 MU TIW × 12 mo

0%

0%

N/A

N/A

0%

Anti-HCV+

HBV DNA+

HBeAg+

15

IFNα 9 MU TIW × 14 wk or 4–6 MU TIW × 12 wk

0%

6.7%

6.7%

6.7%

6.7%

Anti-HCV+

HCV RNA+

HBsAg+

21

IFNα 6 MU TIW × 3 mo + 3 MU TIW × 3 mo + ribavirin × 6 mo

43%

35%

0%

100%

43%

Anti-HCV+

HCV RNA+

HBsAg+

36

IFNα 3–5 MU TIW + ribavirin × 6 mo

69%

11%

0%

0%

56%

Anti-HCV+

HCV RNA+

HBsAg+

42

IFNα 6 MU TIW + ribavirin × 6 mo

69%

31.3%

14.3%

50%

54.8%

HBeAg+

HBV DNA+

HCV RNA+

8

IFN 5 MU TIW × 12 mo + lamivudine × 18 mo

50%

37.5%

0%

37.5%

50%